上海南方模式生物科技股份有限公司 证券代码：688265 证券简称：南模生物 公告编号：2025-057 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 2025 年 9 月 9 日（星期二）至 9 月 15 日（星期一）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过上海南 方 模 式 生 物 科 技 股 份 有 限 公 司 （ 以 下 简 称 " 公 司 " ） 邮 箱 ir@modelorg.com 提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 公司已于 2025 年 8 月 29 日发布公司《2025 年半年度报告》，为 便于广大投资者更全面深入地了解公司 2025 年半年度经营成果、财 务状况，公司计划于 2025 年 9 月 16 日（星期二）13:00-14:00 举行 2025 年半年度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2025 年半 ...

Core Viewpoint - The CXO industry is experiencing a recovery after a period of decline, driven by increased profitability among companies and a favorable capital market environment for stock prices [1][4][10]. Group 1: Industry Performance - In the first half of this year, 16 out of 28 A-share CXO companies reported a year-on-year increase in net profit, a significant rise from only 7 companies in the same period last year, indicating a recovery trend [1][3]. - Among the 28 stocks, 8 companies achieved a net profit increase of over 100%, with Chengdu Xian Dao leading at 390.72% [4]. - The total revenue for WuXi AppTec reached approximately 20.8 billion yuan, a year-on-year increase of 20.64%, with a net profit of about 8.56 billion yuan, up 101.92% [4]. Group 2: Market Dynamics - The recovery in the CXO industry is attributed to three main drivers: active pharmaceutical investment and business development transactions, a shift in global pharmaceutical research focus towards biologics and complex molecules, and technological innovations such as AI in drug development [5][11]. - The overall market for CXO services is expanding as pharmaceutical companies increasingly outsource research and development to specialized firms, which helps reduce costs and improve efficiency [5][11]. Group 3: Company-Specific Insights - Despite the overall recovery, some companies like Tigermed reported declines in both revenue and net profit, highlighting a disparity in performance within the industry [6][8]. - Tigermed's revenue fell to approximately 3.25 billion yuan, a decrease of 3.21%, with a net profit of about 383 million yuan, down 22.22% [6][7]. - Companies with diversified client bases and technological advantages are better positioned to capitalize on market recovery, while those reliant on single business lines may face longer adjustment periods [8]. Group 4: Stock Market Performance - All 28 CXO stocks have seen price increases this year, reflecting the industry's recovery [9][10]. - The stock price increases range from 10% to over 100%, with Nanjing Momo Bio leading at a 142.21% increase [10]. - The stock price performance correlates with improved company earnings, indicating a supportive fundamental backdrop for the sector [10].

Core Viewpoint - The CXO industry is experiencing a recovery after a challenging period, with a significant increase in the number of companies reporting profit growth in the first half of the year, indicating a positive trend in the sector [1][3][4]. Financial Performance - In the first half of this year, 16 out of 28 A-share CXO companies reported profit growth, representing approximately 57.14% of the sector [4]. - Notably, 8 companies achieved a doubling of net profit, with Chengdu Xian Dao leading at a 390.72% increase, followed by Nanmo Biology at 298.69% [4]. - Wu Ming Kang De reported the highest net profit among the companies, with approximately 8.56 billion yuan in net profit, a 101.92% year-on-year increase, and revenue of about 20.80 billion yuan, up 20.64% [4]. - Kang Long Hua Cheng, despite a 37% decline in net profit to approximately 701 million yuan, achieved a record high revenue of 6.44 billion yuan, a 14.93% increase [4][5]. Market Dynamics - The recovery in the CXO industry is driven by three main factors: increased activity in pharmaceutical investment and business development transactions, a shift in global pharmaceutical research focus towards biopharmaceuticals and complex molecules, and technological innovations such as AI in drug development [5][6]. - The overall market for CXO services is expanding as pharmaceutical companies increasingly outsource research and development to specialized firms, which helps reduce costs and improve efficiency [5][6]. Performance Disparities - Despite the overall recovery, some companies like Tai Ge Yi Yao and Yi Nuo Si reported declines in both revenue and net profit, indicating uneven recovery across the sector [6][8]. - Tai Ge Yi Yao's revenue fell by 3.21% to approximately 3.25 billion yuan, with a net profit decline of 22.22% to about 383 million yuan, primarily due to decreased income from clinical trial services [6][7]. Stock Market Trends - All 28 CXO stocks have seen price increases this year, reflecting the industry's recovery [9][10]. - The stock price increases range from 10% to over 100%, with Nanmo Biology achieving the highest increase of 142.21% [10]. - The positive stock performance is supported by improved financial results and a favorable global investment environment in pharmaceuticals [10][11]. Future Outlook - The CXO industry is expected to continue its growth trajectory, driven by an aging global population and increasing health demands, although only companies with core competitive advantages will thrive [11][12].

Market Overview - The Shanghai Composite Index closed at 3813.56 points, with a decline of 1.16% [1] - The total trading volume of A-shares reached 23956.82 billion yuan [1] Technical Analysis - A total of 16 A-shares experienced a crossover where the 5-day moving average fell below the 10-day moving average [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Sichuang Medical (300078) with a distance of -0.91% - Nanmo Biology (688265) with a distance of -0.80% - Shandong Weida (002026) with a distance of -0.75% [1] Individual Stock Performance - Sichuang Medical (300078) saw a decrease of 2.81% with a trading turnover rate of 3.15% [1] - Nanmo Biology (688265) decreased by 0.16% with a turnover rate of 1.39% [1] - Shandong Weida (002026) declined by 2.93% with a turnover rate of 2.90% [1] - Qingda Environmental (688501) dropped by 3.86% with a turnover rate of 1.84% [1] - Pulit (002324) fell by 2.62% with a turnover rate of 2.03% [1] - Other notable declines include: - Meili (000815) down by 4.03% - Hezhong (002383) down by 6.95% [1]

Group 1 - The medical services sector experienced a decline of 1.19% on September 2, with Nanmo Bio leading the drop [1] - The Shanghai Composite Index closed at 3858.13, down 0.45%, while the Shenzhen Component Index closed at 12553.84, down 2.14% [1] - Notable stock performances included Digital Human, which rose by 19.55% to a closing price of 20.30, and TaiGe Pharmaceutical, which increased by 1.78% to 66.25 [1] Group 2 - The medical services sector saw a net outflow of 2.03 billion yuan from main funds, while retail investors contributed a net inflow of 1.307 billion yuan [3] - The table of individual stock fund flows indicates varying levels of investment activity across different companies within the sector [3]

中国经济网北京9月2日讯 南模生物(688265.SH)今日收报56.09元，跌幅6.73%，总市值43.73亿元。 南模生物于2021年12月28日在上交所科创板上市，发行股票数量为1949.09万股，发行价格为84.62 元/股，保荐人（主承销商）为海通证券股份有限公司（现更名为国泰海通证券股份有限公司），保荐 代表人为张子慧、陈亚聪。 南模生物上市首日盘中最高价报82.00元，为该股上市以来最高价。该股目前处于破发状态。 南模生物首次公开发行股票募集资金总额为16.49亿元，扣除发行费用后募集资金净额为14.68亿 元。南模生物最终募集资金净额比原计划多10.68亿元。南模生物于2021年12月23日披露的招股说明书 显示，该公司拟募集资金4.00亿元，分别用于上海砥石生物科技有限公司生物研发基地项目（南方模式 生物）、基因修饰模型资源库建设项目、人源化抗体小鼠模型研发项目、基于基因修饰动物模型的药效 平台建设项目、补充流动资金项目。 南模生物首次公开发行股票的发行费用总额为1.81亿元，其中，保荐及承销费用1.58亿元。 （责任编辑：田云绯） ...

Financial Performance - Company reported total revenue of 196 million yuan for the first half of 2025, a year-on-year increase of 10.69% [1] - Net profit attributable to shareholders reached 18.17 million yuan, up 298.69% year-on-year [1] - In Q2 alone, total revenue was 107 million yuan, reflecting a 14.32% increase compared to the same quarter last year [1] - Q2 net profit attributable to shareholders was 19.13 million yuan, a significant rise of 409.77% year-on-year [1] - Gross margin improved by 18.09% year-on-year, reaching 52.11% [1] - Net margin increased by 279.5% year-on-year, standing at 9.28% [1] - Total expenses (selling, administrative, and financial) amounted to 47.25 million yuan, accounting for 24.14% of revenue, a decrease of 24.05% year-on-year [1] - Earnings per share (EPS) was 0.23 yuan, up 291.67% year-on-year [1] Business Evaluation - The company's return on invested capital (ROIC) was 0.47% last year, indicating weak capital returns [2] - Historical median ROIC since listing is 3.18%, suggesting average investment returns [2] - The company has experienced three years of losses since its listing, indicating a fragile business model [2] - The net profit margin last year was 1.7%, suggesting low added value in products or services [2] Debt and Cash Flow - The company has a healthy cash asset position, indicating good debt repayment capability [2] - Operating cash flow per share was 0.05 yuan, a significant increase of 145.89% year-on-year [1] Accounts Receivable - The accounts receivable situation is concerning, with accounts receivable to profit ratio reaching 1962.96% [2]

Buyback and Reduction Plan - The company repurchased a total of 788,912 shares from February 23, 2024, to May 22, 2024, accounting for 1.0119% of the total share capital, aimed at maintaining company value and shareholder rights [1] - The company plans to reduce up to 779,635 shares, not exceeding 1% of the total share capital, through centralized bidding from September 19, 2025, to December 18, 2025 [2][3] - The repurchased shares will be sold within 12 months after the announcement of the buyback results, and if not sold within three years, the untransferred shares will be canceled [1][3] Shareholder Information - The repurchase account holds 2,346,309 shares, representing 3.01% of the total share capital, which will decrease to 1,566,674 shares, or 2.01%, after the planned reduction [4] - The company has not sold any shares from the repurchase account since its listing [2] Financial Impact - The funds recovered from the share reduction will be included in the company's capital reserve and will not significantly impact the company's operations, finances, or future development [4]

Group 1 - The board of directors of Shanghai Nanfang Model Biological Technology Co., Ltd. held its 24th meeting of the third board on August 28, 2025, with all 9 directors present, including 3 independent directors [1] - The meeting approved several proposals through a voting process, with all votes in favor (9 votes for, 0 against, 0 abstentions) [1][2] - The approved proposals included the 2025 semi-annual report and the special report on the use of raised funds, which were disclosed on the Shanghai Stock Exchange website [1][2] Group 2 - The board also approved a plan for share repurchase and a semi-annual evaluation report on the "Quality Improvement and Efficiency Enhancement Return" action plan, with unanimous support [2]

Group 1 - The core viewpoint of the report indicates that Shanghai Southern Model Biotechnology Co., Ltd. has shown a positive trend in its financial performance for the first half of 2025, with significant increases in revenue and net profit compared to the previous year [1][2]. - Total assets at the end of the reporting period amounted to approximately 1.91 billion yuan, reflecting a slight decrease of 1.06% from the previous year [2]. - The net assets attributable to shareholders increased by 0.52% to approximately 1.69 billion yuan compared to the end of the previous year [2]. Group 2 - The company's operating revenue for the reporting period reached approximately 195.76 million yuan, representing a year-on-year increase of 10.69% [2]. - The total profit for the period was approximately 17.57 million yuan, a significant recovery from a loss of approximately 13.13 million yuan in the same period last year [2]. - The net profit attributable to shareholders was approximately 18.17 million yuan, compared to a loss of approximately 9.14 million yuan in the previous year [2]. Group 3 - The net cash flow from operating activities was approximately 3.67 million yuan, a recovery from a negative cash flow of approximately 8.00 million yuan in the same period last year [2]. - The weighted average return on net assets was 1.08%, a recovery from -0.53% in the previous year [2]. - Basic and diluted earnings per share were both 0.23 yuan, compared to -0.12 yuan in the previous year [2]. Group 4 - The proportion of research and development investment to operating revenue was 21.24%, a slight decrease of 0.7 percentage points from the previous year [2]. - The total number of shareholders at the end of the reporting period was 6,522 [2].